Neovision Capital

Chengdu New Radiomedicine Technology Co.,Ltd. is a Chinese medical isotopes provider. Our business covers research, manufacture and sales for medical isotopes and products. We provide services for malignant tumor diagnosis and treatments and radionuclides medicine technology support and consulting. In April 2016, the company was founded by three co-founders experienced in radionuclides research and development. Jihui Qian, former President of Nuclear Power Institute of China (NPIC), former Deputy Director-General of International Atomic Energy Agency (IAEA); Maoliang Li, former Director of Chengdu Isotopes Institute of NPIC; and Jiming Cai, former Vice President of Sichuan Institute of Atomic Energy. The company is located in Western Airport Development District, Shuangliu, Chengdu, with an area of 71 Are, registered capital of 32.83 million CNY, and total investment of 300 million CNY. The project is listed as "Annual Key Investment Projects of Sichuan Province and Chengdu City in 2017, 2018 and 2019". At present, the company has over 80 employees, with more than 60 R&D specialists, including 1 academician of Chinese Academy of Engineering, 2 experts of Thousand Talent Project, 2 academic and technical leaders from Sichuan province, 10 researchers (associate researchers), and more than 20 people with middle or senior titles. Among them, there are 6 PhDs and over 30 graduates. The proportion of R&D staff has reached 70%, making CNRT the most innovative technology enterprise in the radiopharmaceutical industry in China.

Zhongbo Ruikang focuses on the research and development of domestic tools in the field of cell and gene therapy, mainly to assist customers in realizing the "continuous, closed, disposable, consistent, scalable, automated, modular, and medical deviceization of cell preparation industrialization.

Shanghai Electric (Group) Corporation designs, develops, and manufactures thermal, nuclear, and wind power equipment in China. The company offers gas turbines, transmission and distribution equipment, elevators, machine tools, refrigeration compressors, environmental protection equipment, automation products, rail transportation equipment, machine parts, generators, and other products.

Care Medical is a membrane science platform that focuses on blood purification and biopharmaceuticals.

Media Center is a technology-based corporation that uses technological innovation to boost industrial upgrading. It enables biotechnology and the bioindustry, the employs automation, artificial intelligence, big data, and industrial Internet technologies. Robot scientists free human scientists' hands, unleash their creativity, and raise the time and life value of mental workers, intelligent parallel bioreactors accelerate the R&D cycle, save laboratory space, and reduce R&D costs.

Zhongbo Ruikang focuses on the research and development of domestic tools in the field of cell and gene therapy, mainly to assist customers in realizing the "continuous, closed, disposable, consistent, scalable, automated, modular, and medical deviceization of cell preparation industrialization.

Dakang Medical is a chain of independent blood purification medical service institutions. Dakang Medical is a company whose leading industries are medical investment, medical institution management, and brand operation services.

Xingsai Bio is a developer of single-cell analysis instruments and supporting reagents and consumables.

Maibang Bio provides biomedical process solutions such as R&D and production, customized medium optimization and development services, and liquid medium production. Their cell-culture medium companies might benefit from product performance and optimization development services. Maibang Bio focuses on the development and production of high-end chemically defined media products, the optimized development of customized media services, large-scale dry powder/liquid medium production, and other comprehensive biomedical process solutions.

Nuoyuan Medical is a developer of advanced medical devices that specializes in precision tumor surgery and treatment technology. The company aims to enhance clinical outcomes and optimize resource utilization in healthcare settings. By focusing on innovative solutions, Nuoyuan Medical significantly improves the efficiency of medical professionals while delivering effective treatment options for patients dealing with tumors.

RzonTech is a provider of industrial software products, data services, and overall solutions.

Matrixtime Robotics, founded in 2018 and based in Hongqiao, China, specializes in the development of deep learning and robot vision technology. The company creates advanced artificial intelligence systems designed for industrial applications, enabling factories and manufacturers to enhance their production processes. Matrixtime's offerings include solutions for defect detection, item picking, sorting, and complex machine vision inspection, serving various sectors such as semiconductor manufacturing, photovoltaic energy, automotive precision manufacturing, and unmanned ports. By integrating sophisticated deep learning algorithms into its robotic systems, Matrixtime aims to empower high-end manufacturing and facilitate digital transformation within the industry, ultimately improving production efficiency and reducing quality assurance costs.

Xgene Pharmaceutical Inc. is a late-clinical stage pharmaceutical company established in 2015, based in the Cayman Islands. It focuses on developing small-molecule drugs aimed at treating chronic pain, infectious diseases, and tumors. Utilizing proprietary linker technology, Xgene creates novel, multimodal conjugated molecules that enhance the efficacy and tolerability of pain medications. The company's current programs are dedicated to addressing unmet needs in neurological disorders, making significant strides in the development of innovative treatments for these conditions.

Chineo is a provider of CAR-T immune cell therapy services, specializing in the research and development of innovative cell therapy products aimed at treating tumors and immune diseases. The company focuses on tumor infiltrating lymphocyte therapy (TIL) by integrating high-throughput gene sequencing with CAR-T and other advanced cell therapy technologies. This approach enhances the ability of medical practitioners to diagnose and treat tumors more effectively, contributing to advancements in cancer therapy.

Andisec is dedicated to the research and development of industrial network security technology, products, and services. The company specializes in creating software designed to identify and defend against cyber attacks, viruses, and other cybersecurity threats. By enhancing the security of network systems, Andisec enables industrial enterprises to operate more securely, thereby safeguarding their critical infrastructure and data from potential breaches.

Rimag is a Shenzhen-based company specializing in medical imaging services. Founded in 2014, it operates medical imaging centers that provide examination and diagnostic services, including MRI, CT, PET, X-ray, ultrasound, and mammography. In addition to its imaging center operations, Rimag is involved in the development of relevant cloud technology and the training of professionals in the field. The company generates revenue through its comprehensive range of services, including Imaging Center Services, Imaging Solution Services, and Rimag Cloud Services.

Shenzhen MicroApproach Medical Technology Co., Ltd., established in September 2015, focuses on the research, manufacture, and sale of endovascular medical devices. Recognized as a high-tech enterprise, the company specializes in interventional surgery consumables, including hydrophilic guide wires, ultra-smooth guide wires, and angiography catheters. MicroApproach has formed strong research collaborations with prominent institutions like Beijing Tiantan Hospital and the People's Liberation Army 301 Hospital, enhancing its research and development capabilities. The company emphasizes quality and innovation, striving to provide first-class products for medical professionals and patients while contributing to the advancement of endovascular intervention technologies in China. To support large-scale production, MicroApproach has implemented a comprehensive management system and established a state-of-the-art industrial production line specifically for hydrophilic coating guide wires.

Hualan New Materials is a bio-pharma firm focusing on the production of direct or indirect contact injection pharma packaging materials.

Hocermed is a provider of energy platforms for invasive surgery. They has established research and development bases. They creates a comprehensive system that supports research and development, quality control, production, sales, and service. They supplies products with minimally invasive surgical solutions to healthcare professionals. They also invasive surgical energy devices. They provides surgical products and services to surgeons.

PROPRIUM creates biomedical products and diagnostic techniques intended to serve the biotech field. The company has diagnostic techniques to detect carcinoma, liver, cardiovascular, and cerebrovascular diseases. They offer cancer diagnostics, genetic testing, elisa, lateral flow assays, and personalized medicine.

Allist Pharmaceuticals is a pharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, particularly in the area of cancer treatment. The company addresses unmet clinical needs within the global pharmaceutical market, emphasizing the importance of scientific and technological advancements to improve patient outcomes. Allist Pharmaceuticals is committed to creating safe and effective drugs that are backed by independent intellectual property rights, ensuring that their innovative therapies can meet the diverse needs of patients.

Founded in 2004, Smartee is a leading provider of digital invisible orthodontic solutions in China. As of March 2022, Smartee’s 23.6 million sets of clear aligners have successfully served orthodontic consumers worldwide. Smartee is headquartered in Shanghai, China, and overseas headquarters were established in the UK in 2021. Smartee’s production and R&D base are in Jiaxing Science and Technology City. Smartee currently has over 1,700 employees including a medical team of over 380 members led by professional PhD Orthodontists working in the Smartee Invisible Orthodontic Clinical Medical Center. Our large scale automated intelligent production base in China's "Dental Valley" (Ziyang, Sichuan) serves domestic China and the global market. As one of the leading brands in China’s invisible orthodontics industry, Smartee has introduced 3D printing technology into the field of stomatology instruments production in China and for the first time realized the large-scale production of customized clear aligners. "Innovation" is in the DNA of Smartee. Smartee bracketless invisible orthodontic technology combines clinical stomatology, computer science, biomechanics, 3D printing, and polymer material science, and has achieved a total of over 500 patents since March 2022. Smartee has a database of over 520,000 orthodontic cases, which is growing at a rate of more than 100% per year. It is recognized as one of the most innovative and growing high-tech companies in the field of stomatology R&D and production in China. Smartee's efforts and contributions in promoting the development of the Chinese invisible orthodontic industry have been fully recognized and accepted by all sectors of the industry. It is a member of the 3D Printing Medical Devices Committee of the China Association for Medical Devices Industry, a member of the team that jointly drafted the Chinese oral digitalization wording standard，a standing committee member of the Chinese Stomatological Association, an executive director unit of the Shanghai Medical Instrument Trade Association, and has obtained various honorary titles such as National Hightech Enterprise and Shanghai Little Giant Enterprise. In 2015, KaVo Group, the world's leading manufacturer of dental equipment and consumables, became a shareholder of Smartee, which announced that KaVo Group had made a strategic layout for the promising field of invisible orthodontics. In 2018, Smartee began working with the world-famous University of North Carolina (UNC) School of Dentistry to jointly research and develop orthodontic clinical medicines and clear aligners related to biomechanics and medical polymer materials. In 2019, Smartee officially became a strategic cooperative partner of China Aerospace. The two would fully combine their respective technological and resource advantages and launch a series of strategic cooperations. Smartee joined hands with China Aerospace to advance the development of China's orthodontic industry. Meanwhile, Smartee worked together with the orthodontic team led by Professor Shen Gang to develop Smartee S8 S9 S10 mandibular repositioning invisible orthodontic solutions. Smartee also completed series C funding in the same year. Investors include well known domestic and foreign industry funds and investment agencies in the medical field with solid financial strength. In 2020, Smartee cooperated with the orthodontic team led by Professor Shen Gang for the second time to develop S11 alveolar orthopaedic technology, and for the third time to start the research and development of S12 invisible and fixed fusion orthodontic technology, S16 Invisible forward traction technology. In the same year, Smartee launched a series of innovative products and technology such as multi-layer sheets and S15 Smartee Hook traction technology. In 2021, Smartee continued its cooperation with Professor Shen Gang to develop S17, S18, S19, the mandibular maintenance and perioperative orthodontic solutions. In 2022, Smartee was officially authorized to use Disney and Marvel IPs for its new Smartee Teen products for children and teenagers. With the launching of Smartee Teen, Smartee has been able to provide consumers of all ages with orthodontic correction management. In March 2022, Smartee closed its series D funding round of US$ 80 million. This round of financing will continue to accelerate its expansion in the global orthodontic industry. In the future, guided by brand and driven by innovation and capital, Smartee will adhere to the medical essence of invisible orthodontics and provide safe, efficient, and comfortable invisible orthodontic products and services to global consumers and doctors, and make healthy and beautiful smiles predictable.

Beijing Biostar Technologies, Ltd. was incorporated in Haidian Park, Zhongguancun Science and Technology Park, Beijing, in July 2002. The national high-tech led by the team of Chinese scientists in the United States led by Dr. Tang Li and Dr. Qiu Rongguo. The company, focusing on biomedical development, technology and transfer of anti-tumor small molecule chemical drugs, and technical service consulting, pioneered the creation of new anti-cancer drugs for epothilone in China, and its technology is at the international advanced level.

Rimag is a Shenzhen-based company specializing in medical imaging services. Founded in 2014, it operates medical imaging centers that provide examination and diagnostic services, including MRI, CT, PET, X-ray, ultrasound, and mammography. In addition to its imaging center operations, Rimag is involved in the development of relevant cloud technology and the training of professionals in the field. The company generates revenue through its comprehensive range of services, including Imaging Center Services, Imaging Solution Services, and Rimag Cloud Services.

PANDAINS is an automobile insurance platform.

Automobile insurance sales management platform.

PANDAINS is an automobile insurance platform.

ACROBiosystems Inc. specializes in the manufacture of recombinant proteins for oncological treatments, particularly in the field of cancer immunotherapy. Founded in 2013 and based in Newark, Delaware, the company offers a diverse range of products, including immune checkpoint proteins, targets for CAR-T cell therapy, biosimilar drug targets, and various recombinant proteins such as cytokines and enzymes. Additionally, ACROBiosystems provides pre-labeled proteins, including biotinylated and heavy-labeled collections, as well as kits for quantitative analysis of therapeutic antibodies and inhibitor screening. The company also develops recombinant antigens for SARS-CoV-2 variants and adheres to GMP quality management standards for its cytokine products. ACROBiosystems is dedicated to supplying essential reagents and services necessary for the development of targeted therapeutic drugs.

Oranger is a developer of portable wearable medical devices aimed at treating chronic respiratory diseases, particularly sleep apnea. The company offers remote management services that facilitate diagnosis and treatment at home. Utilizing a cloud-based interactive platform, Oranger provides comprehensive medical services, including screening, clinical evaluation, personalized treatment, and follow-up examinations. This approach empowers patients to effectively manage their conditions and supports their rehabilitation from chronic respiratory illnesses.

Boke Information Co., Ltd. specializes in the research and development of management software and offers management consultancy services in China. The company focuses on creating logistics management solutions that enhance supply chain efficiency through the application of artificial intelligence and machine learning technologies. Boke provides implementation and maintenance services for its software products, catering to various enterprises, government entities, and community organizations. Its innovative approach emphasizes personalized software solutions designed for autonomous configuration, self-expansion, and autonomous maintenance. By supporting clients throughout the entire lifecycle of their IT systems, Boke assists in establishing comprehensive organizational frameworks and ecological structures tailored to their specific needs.

Shanghai Genext Pharmaceutical Technology Co., Ltd operates in the transplant industry in the People’s Republic of China. It offers transplantation drugs and instruments, in-vitro diagnostics, and production bases of medical devices. The company offers TDx, organ preservation and immune function platform, immunosuppressant, and therapeutic drug monitoring equipment, as well as operation accessories. It encompasses various hospital transplants, which include kidney transplant, heart transplant, lung transplant, bone marrow transplant, cell transplant, etc. The company was formerly known as Shanghai Genext Pharmaceutical Technology Ltd. Shanghai Genext Pharmaceutical Technology Co., Ltd was founded in 2003 and is headquartered in Shanghai, the People’s Republic of China.

Founded in April 2014, Renren is the first to enter the used car market in C2C mode. It has developed into a comprehensive car trading service platform integrating used cars and new car transactions, financial services and after-sales services. For second-hand car transactions, Renren provides free door-to-door valuation, sales, replacement and other services for the majority of car owners. In order to strictly control the quality of the car in the sale, the Renren car has established a 249 test standards and a dual detection mechanism through a self-built professional appraisers team, and has reached a cooperation with the China Automobile Dealers Association to become a national standard for second-hand car testing. The industry's first strategic partner in the “certification” certification, the layer of protection is only for the rest of the car. At the same time, for the buyer, the Renren car provides a series of after-sales guarantees such as 14-day returnable car, one-year/20,000-kilometer core component warranty and 200 million yuan guarantee, leading the industry change. In April 2018, Renren was awarded a new round of financing by the Goldman Sachs Group, Tencent, Didi and other investments of $300 million. This is the third time that Tencent has added a Renren car. Previously, Renren had won a strategic investment of 200 million US dollars, and then carried out in-depth cooperation in ecological co-construction, technology, and operation.